2.96
+0.11(+3.86%)
Currency In USD
| Previous Close | 2.85 |
| Open | 3.05 |
| Day High | 2.97 |
| Day Low | 2.7 |
| 52-Week High | 5.89 |
| 52-Week Low | 1.6 |
| Volume | 105,002 |
| Average Volume | 192,506 |
| Market Cap | 111.7M |
| PE | -3.12 |
| EPS | -0.95 |
| Moving Average 50 Days | 3.11 |
| Moving Average 200 Days | 2.86 |
| Change | 0.11 |
If you invested $1000 in Genelux Corporation (GNLX) since IPO date, it would be worth $481.3 as of May 11, 2025 at a share price of $2.96. Whereas If you bought $1000 worth of Genelux Corporation (GNLX) shares 1 year ago, it would be worth $819.94 as of May 11, 2025 at a share price of $2.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
GlobeNewswire Inc.
May 01, 2025 8:05 PM GMT
WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, wil
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
Mar 25, 2025 12:31 PM GMT
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common st
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
GlobeNewswire Inc.
Mar 25, 2025 12:30 PM GMT
– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one partici